Hire an Advanced Robo-Advisor to Trade BMY on Your Behalf.

Stock Detail Header
  • Street Sentiment
  • Personalized Strategy
  • Free Trading Simulator
Get Started
Stock Details
  • PRICE$49.47
  • PRICE CHANGE-$0.25
  • % CHANGE-0.51%
  • TWEETS18
  • CONSENSUSHOLD

Trends

Course of Action

HOLD

Sentiment (10 days)

  •  Strong Buy
  •  Buy
  •  Hold
  •  Sell
  •  Strong Sell

DAILY PRICE CHANGE VS SENTIMENT

  • BullishBullish
  • BearishBearish
  • SentimentSentiment
  • BarPrice

What is Systematic Investing?

Smart Auto-Trading is an advanced automated Portfolio Manager designed to provides investors with a a state of the art automated investment system to invest in the S&P 500®. Its technology is designed to screen, monitor and invest in elite stocks like "BRISTOL-MYERS SQUIBB COMPANY (BMY)". It's Artificial Intelligence augments your potential for profit while eliminating most of the work traditionally involved in stock investing.

What is Smart Auto-Trading good for?

If you are interested in systematic, active investing, Smart Auto-Trading can be a great alternative to passive index funds and ETFs. Smart Auto-Trading uses Artificial Intelligence concepts to screen, monitor and invest in elite stocks. Used in a tax-deferred account such as IRAs and Roth IRAs, it invests systematically using carefully instrumented strategies. Using Smart Auto-Trading is like having a professional Portfolio Manager working for you. You turn it on and it starts working on your behalf.

Smart Auto-Trading actively trades the S&P 500®, day-in and day-out, while you attend more important life events. Because of the systematic nature of Smart Auto-Trading, your account has the potential to grow at a faster rate than if you were to use a passive investment product such as an index fund or ETF. Systematic active trading using Artificial Intelligence holds the potential to grow your account faster.

Using Smart Auto-Trading is Easy

To connect Smart Auto-Trading to your account you will need to open an account with one of our Broker / Dealer partners in the United States. Our Partners offer very competitive services and flawless execution.

Benefits

There are clear benefits associated with using Smart Auto-Trading to help you reach your financial goals. Smart Auto-Trading simplifies stock investing down to a few easy steps. It systematically invests for you, using your personalized strategy.

Using Smart Auto-Trading is like having a professional Portfolio Manager working for you to help you reach your financial goals.

Smart Auto-Trading actively invests which is different from passive investing. Our automated solution is on the lookout, working to maximize your potential every minute of a business day. It 'trades on the news' taking advantage of changes.

Smart Auto-Trading is one of the first platform to take advantage of Government grade listening technology to monitor and classify securities.

Try Smart Auto-Trading today!

You can test Smart Auto-Trading in simulation mode, risk free, Stock Circles today.

Get started now - and see where active automated trading can take you.

Disclaimer: Past performance may not be indicative of future results. Therefore, you should assume that the future performance of any specific investment and systematic investment strategies will be profitable. Smart Auto-Trading, like other investment methods, rely on favorable market conditions to provide positive outcomes.

BRISTOL-MYERS SQUIBB COMPANY (BMY) News

Bristol-Myers Squibb Reports First Quarter Financial Results

Increases First Quarter Revenues 5% to $5.2 Billion.

Posts First Quarter GAAP EPS of $0.91 and Non-GAAP EPS of $0.94.

Achieves Important Clinical and Regulatory Milestones in Oncology.

Opdivo plus Yervoy Approved in the U.S. for Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma.

Opdivo Four-Week Dosing Approved in the U.S. and Europe.

Applications for Opdivo plus Yervoy for Previously Treated Patients with MSI-H or dMMR Metastatic Colorectal Cancer and Opdivo for Previously Treated Patients with Small Cell Lung Cancer Accepted for Priority Reviews in the U.S.

Presents Important New Data on Immuno-Oncology Portfolio at AACR Including Phase 3 Data for Opdivo plus Yervoy in First-Line Advanced Non-Small Cell Lung Cancer Patients with High Tumor Mutational Burden.

Get Started today! - Risk Free

Investors who like BRISTOL-MYERS SQUIBB COMPANY (BMY) also like

Most Talked About Stocks on Stock Circles

Stock Bubbles